Ian Sollom MP: speeches
4 Jul 2025–3 Jul 2026
How these years work
Our reporting years run from 4 July to 3 July, starting with the 2024 general election. They are not official parliamentary sessions. Office costs keep IPSA’s April–March financial years. Records may cover only part of a year; a missing record does not mean no work was done.
Parliamentary contributions: dates and coverage
- Source checked
- 19 Nov 2026
- Last successful import
- 19 Nov 2026
- Records dated through
- 18 Nov 2026
- Selected period
- Reporting year 2: 4 Jul 2025 to 3 Jul 2026
- Completeness
- Published snapshot: 20,988 records in the source window 21 Aug 2026 to 19 Nov 2026. The published snapshot covers its stated source window. Older imports can extend beyond it; not every public speech is included.
This page lists the parliamentary spoken contributions we hold for Ian Sollom in the reporting year 2 (4 Jul 2025 to 3 Jul 2026). It does not include every public speech, party-conference address or constituency event. Latest retained contribution in this period: 3 Dec 2025. The source check date and dataset limits are shown above. Open the Hansard link for the full debate and surrounding context.
Read what this MP said, asked and contributed in Parliament.
2 published records · newest first.
Speeches
- 3 Dec 2025 · Oxford to Cambridge Growth Corridor · Read the full contribution in Hansard
More
It is a pleasure to serve with you in the Chair, Sir Jeremy. I congratulate the hon. Member for Cambridge (Daniel Zeichner) on securing the debate. The Oxford-Cambridge growth corridor has had something of a tortured history. For nearly two decades, various iterations of the vision have promised transformational change, only to be shelved, rebranded or, as was reported in 2022, flushed down the toilet in mime by a previous Secretary of State, who is fortunately no longer here.
- 11 Sep 2025 · Life Sciences Investment · Read the full contribution in Hansard
More
I welcome the Minister to his place. It is incredibly disappointing that MSD has pulled out of this billion-pound investment in the UK, including the loss of more than 100 jobs in important life sciences infrastructure. However, this has been on the cards for some time, and the warnings to Government have fallen on deaf ears. Earlier this year, AstraZeneca also cancelled planned upgrades to its production, and Novartis has described the UK as “largely uninvestable”.
Explore activity by topic or department
Contributions by debate topic
4 Jul 2025–3 Jul 2026. Existing keyword taxonomy applied to official debate titles and contributions; a contribution may appear in more than one topic and unclassified records are retained.
View as listWhat this shows and doesn't show
Published records only — not a full account of an MP’s work. How we work →